This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

This study has been withdrawn prior to enrollment.
(No participants. IND denied by FDA.)
Sponsor:
Information provided by (Responsible Party):
Tom Jaksic, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01263574
First received: December 17, 2010
Last updated: June 20, 2017
Last verified: June 2017
  Purpose
This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome. While ethanol locks have been used safely in children, there has been no published research to date that clearly shows it is of definite benefit in this group of patients.

Condition Intervention Phase
Catheter Related Infections Short Bowel Syndrome Drug: 70% ethanol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Prevention
Official Title: Trial of Ethanol Lock Therapy to Prevent Catheter Associated Blood Stream Infections

Resource links provided by NLM:


Further study details as provided by Tom Jaksic, Boston Children's Hospital:

Primary Outcome Measures:
  • Catheter associated blood stream infection (CABSI). [ Time Frame: Number of infections reported per 1000 catheter days. ]
    Published data in intensive care unit (ICU) patients with CABSI has noted that central venous catheter cultures had a specificity of 98% and a negative predictive value of 97%. In our study, we will define CABSI as a positive central venous catheter blood culture in the face of clinical signs of infection, when the catheter has been used in the last 48 hours prior to infection, and without other obvious source of infection. CABSI rate will be reported as number of infections per 1000 catheter days after 12 months of follow up.


Enrollment: 0
Anticipated Study Start Date: February 2011
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Heparinized Saline
This group will maintain their central lines patent with heparinized saline.
Drug: 70% ethanol
Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Other Name: ethanol lock
Experimental: Ethanol lock solution group
Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
Drug: 70% ethanol
Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Other Name: ethanol lock

  Eligibility

Ages Eligible for Study:   3 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age >3 months
  • Intestinal failure patients
  • Silicone catheter for the administration of parenteral nutrition

Exclusion Criteria:

  • Age < 3 months
  • Weight < 5 kg
  • Documented allergy to ethanol
  • Evidence of tunnel site infection
  • Patients receiving continuous renal replacement therapy
  • Concomitant use of metronidazole
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01263574

Locations
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children’s Hospital
Investigators
Principal Investigator: Tom Jaksic, M.D, Ph.D Boston Children’s Hospital
Principal Investigator: Christopher Duggan, M.D, MPH Boston Children’s Hospital
  More Information

Responsible Party: Tom Jaksic, W. Hardy Hendren Professor of Surgery, Harvard Medical School, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT01263574     History of Changes
Other Study ID Numbers: 09-03-0132
Study First Received: December 17, 2010
Last Updated: June 20, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Tom Jaksic, Boston Children's Hospital:
Catheter related infections prevention/control
Anti infective agents
Catheter related infections prevention

Additional relevant MeSH terms:
Infection
Communicable Diseases
Syndrome
Short Bowel Syndrome
Catheter-Related Infections
Disease
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 28, 2017